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that induce long-lasting protection (Olsson et al., 2007). It is
not known what level of antibodies indicates an individual’s
ability to fend off HPV infection, but the available data do
suggest that HPV vaccines would provide a lengthy period of
protection, likely to usher a vaccinated individual through
the years of highest infection risk and beyond. Additional
studies are ongoing to verify these projections. Based on
demonstrated clinical efﬁcacy and favorable safety proﬁle,
this quadrivalent HPV prophylactic vaccine is being intro-
duced as a cost-effective means for reducing the morbidity
and mortality of cervical/anogenital cancers, as well as the
emotional and economic burdens of abnormal Pap tests and
genital warts. Compared to a vaccine containing VLPs of only
HPV types 16 and 18, the reduction of HPV-associated dis-
ease burden is anticipated to be signiﬁcantly higher with the
administration of the quadrivalent HPV vaccine, since HPV 6
and 11 are responsible for approximately 90% of all genital
warts and 15% of low-grade cervical neoplasias. The quadri-
valent HPV vaccine is the ﬁrst and only to show 100% efﬁcacy
against HPV 6, 11, 16 and 18-related external genital lesions
including genital warts, vulvar and vaginal cancers. More-
over, the prevention and cost-savings from HPV 6/11 related
diseases will begin relatively early in the ﬁrst years follow-
ing vaccine introduction making the quadrivalent vaccine
particularly attractive to national policy-makers.
doi:10.1016/j.ijid.2008.05.085
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For several years, the Macroepidemiology of Inﬂuenza Vac-
cination Study Group (MIVSG) has documented inﬂuenza
vaccine distribution, recommendations and reimbursement
in an increasing number of countries throughout the world.
In 2003, 56 MIVSG countries used 275 million (M) doses,
94% of the 292M doses distributed worldwide. By 2005, the
MIVSG had grown to include 73 countries. These countries
used approximately 330M doses of seasonal vaccine. In most
countries, levels of vaccine use (doses distributed/1000
total population) showed relatively little change between
2002, the year before the re-emergence of H5N1 inﬂuenza,
and 2005, although large differences persisted between
individual countries. However, six countries (Belgium, El
Salvador, Japan, Latvia, Malta and Mexico) showed substan-
tial increases in vaccine use over this period, and Malta’s
increase from 124 to 657 doses/1000 was remarkable. In a
few countries, vaccine use decreased, sometimes due to
supply shortages. Some form of public reimbursement for
vaccination was provided in approximately 60% of the sur-
veyed countries, and they tended to have higher levels of
vaccine use compared with countries with no public reim-
bursement. Vaccination recommendations for risk groups
showed little change compared with earlier years, although
the age cut-off levels for vaccinating older adults decreased
in several countries. More interesting, by 2005, seven coun-
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ries had adopted policies for vaccinating children 6-23
onths in age. In the US, the upper age limit for children
as extended to 5 years in 2006 and to 18 years in 2008.
In 2005, nine vaccine-producing countries used 59% of
ll doses of seasonal inﬂuenza vaccine, but had only 12%
f the world’s population. Inﬂuenza vaccination is gradually
ncreasing in many countries, especially in those with rapidly
eveloping economies. This growth in seasonal vaccine use
ill lay the foundation for vaccination programs when the
ext pandemic occurs.
oi:10.1016/j.ijid.2008.05.086
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he intradermal (ID) route of immunization has a fair claim
o primacy since the smallpox vaccine was administered via
he skin for almost 100 years before the next human vaccine
as introduced. Despite this early success and long-standing
mmunological interest in this route, the large majority of
urrent vaccines are administered either via the intramus-
ular or subcutaneous routes. The accessibility of the skin
s obvious and the potential immunological advantages of ID
mmunization have been known for some time. Animal mod-
ls of ID vaccination have generally yielded excellent results
ith a range of microbial antigens and several ID vaccines
ave been successfully introduced for human infections such
s rabies and hepatitis B. The skin is the largest immune
organ’ of the human body and, unlike subcutaneous and
uscle tissues, the skin has evolved speciﬁcally to limit the
enetration of chemical andmicroorganisms. As a result, the
kin is better prepared than most tissues to actively screen
or invasive microbes and to mount appropriate innate and
daptive immune responses. The immunologic characteris-
ics and capabilities of the skin have been the subject of
onsiderable research for many years due to this unique
front line’ position. Until recently however, full exploita-
ion of the potential of the ID route for vaccination has been
ampered by the lack of simple, reliable and safe injection
ystems. Recent advances in delivery system technologies
ave sparked renewed interest in the ID route for both
stablished and new vaccines. This presentation will provide
n overview of the potential immunological and practical
dvantages of ID vaccination as well as a brief review of
istorical and recent ID vaccination techniques.
oi:10.1016/j.ijid.2008.05.087
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linical Development of a Seasonal Inﬂuenza Vaccine by
ntradermal Micro-injection
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ackground: Annual trivalent inactivated inﬂuenza vaccines
TIV) provide protection for hundreds of millions of individu-
ls worldwide. Yet there is need to improve vaccine efﬁcacy
